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I. INTRODUCTION
On December 13, 1994, David Kessler, the Commissioner of the Food and
Drug Administration (FDA), spoke at the Food and Drug Law Institute's 38th
Annual Education Conference and declared an \FDA initiative to obtain more
pediatric data throughout the drug development period and in labeling."1 The
Commissioner was speaking of the urgent need for more drug testing on children
to determine appropriate pediatric use and the urgent need for an increase in
the overall proportion of prescription drugs that bear labels indicating pediatric
use.
Unfortunately, all children get sick. These illnesses may include any-
thing from the common cold, strep throat, and the u to asthma, diabetes,
cancer, and AIDS. Some children will require anesthesia, emergency medical
drugs, or neurological drugs. Children may need commonly prescribed drugs or
they may need experimental drugs. Regardless of these facts, more than 75%
of the drugs on the market in our country today have not been tested for either
safety or eectiveness in fetuses, infants, or children.2 In addition, only ve of
the eighty drugs hospitals use most frequently to treat infants and newborns
1David A. Kessler, Remarks by the Commissioner of Food and Drugs, 50 Food & Drug
L. J. 327, 330 (1995).
2See Victor Ostrowidski, Infants, Kids, and Drugs, Am. Druggist, May 1994, at 16, 16.
1are actually labeled for pediatric use.3 Doctors are still able to prescribe these
drugs for children because once a drug is approved by the FDA, medical profes-
sionals can legally prescribe the drug for unapproved, o-label uses.4 As deputy
director of the FDA's Oce of Drug Evaluation I, Paula Botstein, indicated,
\physician labeling [usually] includes a disclaimer that says safety and eective-
ness have not been established for use in children."5
This is a problem that requires immediate attention. Children are not
just miniature adults; a child metabolizes and absorbs drugs dierently than
adults, making drug testing and labeling regarding pediatric use essential.6 This
paper rst addresses these needs in more detail. The histories of drug testing
on children and labeling drugs for pediatric use are next addressed. Then this
paper considers the current conditions of, and regulations on, drug testing and
pediatric labeling. Finally, an analysis of what needs to be done to make drugs
more safe and eective for use in children is given.
II. THE HEALTH AND SAFETY OF CHILDREN REQUIRE MORE DRUG
TESTING ON CHILDREN AND MORE DRUGS LABELED FOR
PEDIATRIC USE
3This refers to drug labels bearing information such as the dosages, indications, and con-
traindications for use in children. See id.
4See 21 C.F.R. x 312.2(d) (1996).
5Why FDA is Encouraging Drug Testing in Children (last modied Jan. 1995) <http://
fdabbs.fda.gov/fdac/special/newdrug/kidmed.html> [hereinafter Drug Testing in Children].
6See id.
2Growth, dierentiation, and maturation make children dierent from adults.
Childhood brings about dramatic changes in body proportions, composition,
and physiology; dierentiation, growth and maturation of major organ systems;
rapid increases in length, weight and surface area; and changes in the propor-
tion of body weight made up by fat, protein, and water.7 Changes in both
metabolism and excretion throughout childhood,8 require drug testing on chil-
dren to determine appropriate dosages; this information should then appear on
drug labels so that physicians can prescribe drugs for children appropriately.
While having this information seems logical, these vital facts are gen-
erally unknown. The FDA is nally facing complaints that health care profes-
sionals are \giving `guesstimate' dosages of drugs to babies and children because
little or no research has been done on the proper dosages."9 In 1990 the Amer-
ican Academy of Pediatrics estimated that 80% of drugs approved for adults,
contained no information pertaining to pediatric use.10 The result is that chil-
dren are dying either because doctors will not prescribe the drugs that they
need or because the drugs are administered improperly.11A. Drug Testing and
Children: A Desperate Need
\[I]t's important to gure out what doses work best in kids and what
7See Ralph E. Kauman, Scientic Issues in Biomedical Research with Children, in Chil-
dren as Research Subjects 29, 29 (Michael A. Grodin & Leonard H. Glantz eds., 1994).
8See id.
9Robin E. Margolis, Regulatory Update, 12 No. 1 HealthSpan 24, 25 (1995).
10See Specic Requirements on Content and Format of Labeling for Human Prescription
Drugs; Revision of \Pediatric Use" Subsection in the Labeling, 59 FED. REG. 64240, 64240
(1994); Rule Would Help Doctors Prescribe Drugs for Children, The Des Moines Reg., Dec.
13, 1994, at 6 [hereinafter Rule Would Help Doctors].
11See Rule Would Help Doctors Prescribe Drugs for Children, supra note 10, at 6.
3kinds of adverse reactions are likely to occur,"12 says Paula Botstein, deputy
director of FDA's Oce of Drug Evaluation I, when asked why the FDA is en-
couraging drug testing in children. While there are advances in medicine every
day, children are typically left out because pediatricians do not know how to
properly prescribe these new medications since there has been no prior testing
on children.13 This is the case with both FDA approved drugs, such as many
antibiotics and anesthesias, as well as many experimental drugs used for diseases
such as cancer and AIDS.
The problem is that \children are not little adults, when it comes to
calculating doses or anticipating side eects,"14 said Dr. Edwin Forman, profes-
sor of pediatrics at Brown and director of the children' cancer center at Rhode
Island Hospital.
Young children metabolize, absorb, and excrete drugs at dierent rates
than adults.15 These rates are key to determining the proper doses and dosing
intervals for children.16 In addition, the processes of growth and development
aect the potential for a medication to be toxic to a child.17
There are many examples showing how these biological dierences lead
children and adults to react dierently to the same drugs. For example, some
barbiturates make children hyperactive, but make adults feel sluggish.18 Am-
12Drug Testing in Children, supra note 5.
13See Irene Wielawski, Drug Advances Leave Children out in the Cold; Few New Medicines
are Being Tested on Youngsters, L.A. Times, Jan. 9, 1990, at E1.
14Id.
15See Drug Testing In Children, supra note 5; Kauman, supra note 7, at 38.
16See Kauman, supra note 7, at 38.
17See id. at 39.
18Rebecca D. Williams, How to Give Medicine to Children (last modied Dec. 1996)
<http:// www.fda.gov/fdac/features.196 kid.html>.
4phetamines stimulate adults, but can make children more calm.19 Aspirin, while
an over-the-counter drug, clearly exemplies this point as it can lead to Reye's
Syndrome in children with chickenpox or u symptoms, but this does not hap-
pen in adults.20
Despite all of these known dierences, the current level of drug testing
in children is not sucient. One reason that children are not used in clinical tri-
als relates to the ethics involved in drug testing on children. Obtaining consent
is an integral component to using children in clinical trials. Young children are
not capable of providing their own consent and so it is typically left to parents.21
Another ethical concern is giving a sick child a placebo instead of a drug that
could be a potential cure.22 Lastly, it is morally troubling, as well as dicult,
to nd healthy child subjects to use in clinical trials. Thus, typically children
that are used for drug testing have the disease.23
There are other roadblocks in the area of pediatric drug testing. First
of all, the Federal Food, Drug, and Cosmetics Act does not authorize the FDA
to require testing on children prior to approving a drug for the market.24 If
Congress amended the statute, the result would probably be an increase in the
current average of seven to ten years it already takes for the FDA to approve
New Drug Applications (NDAs).25 In addition, the nancial costs of such a
19See id.
20See id.
21See Leonard H. Glantz, The Law of Human Experimentation with Children, in Children
as Research Subjects, supra note 7, at 103, 104. See discussion infra Part IV(A)(3).
22See Ken Flieger, Testing Drugs in People (last modied Jan. 1995)
<http://fdabbs.fda.gov/special/newdrug/testing.html>.
23See id.
24See 21 U.S.C. x 301{395 (1996); Wielawski, supra note 13.
25See Wielawski, supra note 13, at E1.
5requirement could stie innovation, as drug companies shirked the expense of
drug testing on children by not developing new and better drugs. Finally, an-
other reason for the limited quantity of drug testing in children is that seriously
ill children constitute a very small proportion of the market, leaving pharmaceu-
tical companies without the nancial incentives to test the drugs on children.26
For example, only 1.5% of those aicted with HIV are children,27
which helps to explain why the new class of AIDS drugs, protease inhibitors,
have only been tested and licensed for use in adults.28 A Milwaukee pediatrics
AIDS physician has prescribed the drug for two children, but severely criticized
the pharmaceutical industry saying that he has no information about the proper
dosage or the side eects in children. He says that this is because there is no
economic incentive for testing the drug on children since most AIDS patients
are adults.29 This is not a problem limited to protease inhibitors. Only three
of the nine AIDS drugs currently available have been approved for children.30
In addition, other drugs primarily used by adults such as high blood pressure
medication, ulcer medication, 31 and inhaled asthma drugs,32 have not been
tested on children.
Children deserve as much of a chance to live as adults. The immorality
26See id.; Drug Testing in Children, supra note 5.
27See Debra Gordon, Leaving the Children Behind; HIV Treatment: For Adults Only?,
The Virginian Pilot, Nov. 29, 1996, at A1.
28See Marilyn Marchione, Two Area Children Being Treated Experimentally with New Class
of AIDS Drugs, Milwaukee J. Sentinel, Nov. 30, 1996, at 3.
29See id.
30See Gordon, supra note 27, at A1; Pharmacia & Upjohn Rescriptor not Recommended
for Use with Protease Inhibitors, FDA Committee Says, 58 F-D-C Rep. (\The Pink Sheet"),
Dec. 2, 1996, at 18.
31See Elizabeth Stone, Kids' Dosages Debated, Chicago Tribune Co., Jan. 31, 1995, at 7.
32See Wielawski, supra note 13, at E1.
6in this situation lies with the pharmaceutical company that does not test drugs
on children because it is not cost-eective. The problem here is clear; there is
an urgent need for an increase in drug testing on children.
7B. Pediatric Use Labeling: Another Desperate Need
If a drug is not tested on children then the drug label will almost al-
ways bear nothing relevant to usage in children.33 Since so few drugs are tested
for safety and eectiveness in children, it is appalling, but not shocking, that
75-80% of all drugs have no pediatric information on the label.34
While there is little testing and little information on labels, health
professionals can still prescribe a drug for a child as an o-label use. Thus,
over time, these medical experts can gain experience with a drug and determine
what dosage is appropriate for a child. Anesthesia drugs, which are often pre-
scribed for children, but are not specically approved or labeled for children,
are a good example of how professionals learn through trial and error what the
proper dosages are.35 This informal testing of drugs on children is integral to
calibrating appropriate dosages. Once physicians have gured these levels out
(albeit not in the most favorable manner), this information should be on the
drug label so that other physicians need not go through the trial and error pro-
cess.
Cancer drugs for children provide a clear example of the need for pe-
diatric use labeling. Dr. Edwin Forman, director of the children's cancer center
at Rhode Island Hospital explained that cancer drugs are very toxic and can
therefore have very serious side eects, especially when improper dosages are
33The 1994 regulation, which will be discussed in detail later in this paper, is aimed at
changing this. Currently, almost all drugs used by children still do not have labels indicating
pediatric usage.
34See Specic Requirements on Content and Format of Labeling for Human Prescription
Drugs; Revision of \Pediatric Use" Subsection in the Labeling, 59 FED. REG. 64240, 64240
(1994).
35See Drug Testing in Children, supra note 5; Rule Would Help Doctors Prescribe Drugs
for Children, supra note 10.
8given. These drugs, he says, are marketed for adults before they are tested on
children. Dr. Forman is part of the Pediatric Oncology Group, an organization
which maintains a data bank regarding the use of these drugs on children so that
the pediatricians can share their experiences with the drugs.36 Unfortunately,
there are not enough networks like this to replace the need for pediatric use to
appear on the labels.37
On December 13, 1994, the FDA promulgated a nal rule revising pe-
diatric use labeling.38 The pharmaceutical companies have extended the com-
pliance deadline of this rule until April 7, 1997,39 but it hopefully will increase
the amount of drugs bearing pediatric labeling. The FDA's justication for this
rule eectively conveys the need for pediatric use labeling:
FDA continues to be concerned that, without adequate
information,
practitioners may be reluctant to prescribe certain drugs for their pe-
diatric
patients, or may prescribe them inappropriately, choosing dosages, for
instance, that are arbitrarily based on the child' age, body weight, or
body
surface area without specic information as to whether this is appro-
priate.
As a result, pediatric patients may be exposed to an increased risk of
adverse
reactions, or decreased eectiveness of the drugs prescribed, or may be
denied access to valuable therapeutic agents.40
III. A HISTORICAL ANALYSIS
36See Wielawski, supra note 13, at E1.
37See id.
38See Specic Requirements on Content and Format of Labeling for Human Prescription
Drugs; Revision of \Pediatric Use" Subsection in the Labeling, 59 FED. REG. at 64240.
39See Specic Requirements on Content and Format of Labeling for Human Prescription
Drugs; Revision of \Pediatric Use" Subsection in the Labeling; Extension of Compliance Date,
61 FED. REG. 68623, 68623 (1996).
40Specic Requirements on Content and Format of Labeling for Human Prescription Drugs;
Revision of \Pediatric Use" Subsection in the Labeling, 59 FED. REG. at 64240.
9A. The History of Drug Testing on Children
Societal treatment of children has varied immensely and the history of
drug testing on children reects the trends. In essence, as society became more
concerned with child welfare, the use of children in drug testing became more
obsolete. It is only somewhat recent that using children in clinical trials has
been viewed as a practice that could be consonant with child welfare.
Very early history reects the \relative social invisibility of children"
as they were virtually excluded from medical discussions.41 Although the Hip-
pocratic texts from the third century BC had some discussion of childhood
diseases and suggested that children were not just little adults, there was no
systematic discussion of pediatric care.42 The rst English, pediatric medical
text was probably Thomas Phaire's 1545, Book of Children.43
The eighteenth century was a period marked by the indenturing of chil-
dren, who became seen as valuable economic commodities.44 In terms of medical
experimentation, adults were using children (and slaves) as their research sub-
jects.45 For example, in response to the smallpox epidemic in England, Zadiel
Boylston attempted variolation on his two sons and his two slaves.46 Soon vac-
cination, inoculating people with small amounts of the disease, became popular.
Jenner vaccinated his one-year old son with smallpox.47 Physician, Benjamin
41Susan E. Lederer & Michael A. Grodin, Historical Overview: Pediatric Experimentation
in Children as Research Subjects, supra note 7, at 3, 4.
42See id.
43See id.
44See Tim Hacsi, From Indenture to Family Foster Care: A Brief History of Child Placing
in History of Child Welfare 155, 156 (Eve P. Smith et al. eds., 1996).
45See Lederer & Grodin, supra note 41, at 4.
46See id.
47See id. at 5.
10Waterhouse, vaccinated eight of his children with smallpox and then tested the
eectiveness by exposing three of them to people aicted with smallpox.48 In
1801, Nathaniel Chamman inoculated children from the Philadelphia Almshouse
with measles.49
The Industrial Revolution made children even more economically valu-
able and therefore protected. It was at this time that childhood was seen as a
distinct phase of development. Only poor children were indentured.50 In the
1850s, the rst children's hospitals opened in New York and Philadelphia and
in 1888 the American Pediatric Society was rst established.51 The Society for
the Prevention of Cruelty to Children (SPCC) was formed in the 1870s; many
children thought to be abused or neglected were then placed in orphan asylums
or institutions.52 The poor social conditions of the late nineteenth century left
many of these institutions ripe for epidemics; pediatricians tried to help these
children.53 Alfred Hess, medical director of the Hebrew Infant Asylum in New
York City, began experimenting on the institutionalized children and Walter
Reed and George Miller Sternberg studied smallpox on the children in Brook-
lyn orphanages.54 In 1885, Louis Pasteur administered the rst rabies vaccine
to a nine year old boy who had been bitten fourteen times by a rabid dog.55
Remember, however, the late nineteenth century was also a period
48See id.
49See id.
50See id at 6.; Hacsi, supra note 44 at 158. Indenturing was sending children to live with
other families to work on their property and learn a trade.
51See Lederer & Grodin, supra note 41, at 6.
52See Hacsi, supra note 44, at 163.
53See Lederer & Grodin, supra note 41, at 6.
54See id. at 6-7.
55See id. at 7.
11when children came to be valued as demonstrated by the formation of the So-
ciety for the Prevention of Cruelty to Children and the American Pediatric
Society. Attempts were made to seek out and rescue children from abuse and
poverty.56 Thus, there was also criticism of the use of children for experi-
mentation. For example, Arthur Howard Wentworth performed spinal taps on
twenty-nine children and then released a report saying that this process was
momentarily painful, but essentially harmless.57 The publication of his study
produced enormous backlash.58
By the early twentieth century, as a result of the Wentworth study,
state legislators were considering bills which would have prohibited experimen-
tation on children, but none were enacted.59 Alfred Hess, of the Hebrew Or-
phan Asylum, was also criticized for using \orphans as guinea pigs."60 After
several children died from the distribution of tetanus-infected diphtheria anti-
toxin, Congress passed the Biologics Act of 1902, which required the licensing
of biological drugs sold in interstate commerce.61
There was, however, almost no federal policing of the treatment of
children during much of the rst half of the twentieth century. Thus, in the
drug experimentation arena, there were no guidelines for the use of human sub-
jects. The scientic community and bad publicity did serve as the impetus for
some scientists to obtain parental consent prior to drug testing on children.62
56See Hacsi, supra note 44 at, 163.
57See id. at 11.
58See id. at 12.
59See id..
60Id. at 13.
61See Thomas A. Hayes, Drug Labeling and Promotion: Evolution and Application of Reg-
ulatory Policy, 51 Food and Drug L.J. 57, 59 (1996).
62See id. at 14.
12In 1935, scientists, such as John Kolmer and Maurice Brodie, tested their polio
vaccines on themselves, their own children, and then small groups of children
whose parents had volunteered them before they tested them on large numbers
of children.63 1935 was also the year for enactment of Title IV of the Social
Security Act, Aid to Dependent Children.64 This Act increased the funds avail-
able for poor families so that many of the families that would have turned to
orphan asylums or child-placing agencies were able to keep their children.65
These changes led to a trend towards preventing child abuse and neglect, rather
than rescuing children from poverty.66 Amidst this political and social back-
ground, Kolmer and Brodie were soon denounced as murderers for the many
deaths they caused with their experimental polio vaccines.67
World War II brought about more governmental involvement in pro-
tecting children. Foster care became a popular alternative to institutions so
that children could be raised in familial settings.68 The Committee for Medical
Research (CMR) assessed applications to perform medical research on children
in orphanages.69 Government interest in medical research grew tremendously
after the War as appropriations for the National Institiute of Health (NIH)
grew from $700,000 in 1946 to over $55 million in 1955.70 In addition, after
World War II, the world was appalled by the experiments performed on those
63See id. at 15.
64See Hacsi, supra note 44, at 167.
65See id.
66See Roger J.R. Levesque, The Failures of Foster Care Reform: Revolutionizing the Most
Radical Blueprint, 6 Md. Contemp. Legal Issues 1, 5 (1994-1995).
67See Lederer & Grodin, supra note 44, at 15.
68See Hacsi, supra note 44 at 167.
69See Lederer & Grodin, supra note 44, at 15.
70See id. at 16.
13in concentration camps. The Nuremberg Code was issued in 1948, delineating
standards for medical ethics.71
While there still were no federal child abuse or human research sub-
ject statutes on the books, the 1960s were a time for concern about welfare. In
1962, the article, Battered Child Syndrome was published72 and in 1966 Henry
Beecher published an ethical critique of clinical experimentation in the New
England Journal of Medicine.73 In 1962 the Kefauver-Harris Amendments to
the Food, Drug, and Cosmetics Act mandated informed consent of all human
subjects.74 The FDA strengthened this policy in 1967 by requiring the consent
to be in writing.75
From 1950-1970 there were studies of the hepatitis virus at the Wil-
lowbrook State School, an institution for severely mentally retarded children.76
As opposed to the vaccine trials, these hepatitis trials involved the intentional
infection of the children with the hepatitis virus.77 While there was parental
consent for the trials, Henry Beecher again criticized the experimentation saying
that parents were not adequately informed of the risks, that it was problematic
for children to participate when there were no anticipated therapeutic benets,
and that it was unethical for parental consent to be used as an admissions cri-
terion to the overly crowded institution.78
71See Richard C. Thompson, Protecting Human Guinea Pigs (last modied Jan. 1995)
<http://fdabbs.fda.gov/fdac/special/newdrug/guinea.html>.
72See Hacsi, supra note 44, at 168.
73See Lederer & Grodin, supra note 41, at 16.
74Drug Amendments of 1962, Pub. L. No. 87-781, 76 Stat. 780 (1962) (codied as amended
at 21 U.S.C. x 355(I)(3). See also Thompson, supra note 71.
75See id..
76See Lederer & Grodin, supra note 41, at 17.
77See id. at 18.
78See id.
14The seventies became a time for regulation. In 1974, the Child Abuse
Prevention and Treatment Act 79 was enacted as a federal attempt to recognize
and eliminate the devastating problem of child abuse. Similarly, the federal
government acknowledged its need to protect research subjects.
On October 9, 1973 a notice of proposed rule-making was published in
the Federal Register suggesting regulations that would require committee ap-
proval for any research supported by a Department of Health, Education and
Welfare grant or contract which involved risk to human subjects.80 In Novem-
ber 1973, a draft document regarding the protection of human subjects was
published in the Federal Register, which regarded, \[i]nformed consent [as] the
keystone of the protection of human subjects involved in research, development,
and demonstration activities."81 Children, prisoners, and the mentally inrm
were identied as people having limited capacities to make informed choices.
It proposed additional regulations for these vulnerable populations.82 On May
30, 1974, nal guidelines for the protection of human subjects were published
in the Federal Register, but they made no explicit reference to the protection
of children.83 As the proposal indicated, this rule ensured that any activity
supported by a Department of Health, Education, and Welfare grant or con-
tract involving human subjects would be reviewed and approved to determine
whether the benets outweighed the risks, whether the rights and welfare of
79Pub. L. No. 93-247, 88 Stat. 4 (1974).
80See Protection of Human Subjects, 38 FED. REG. 27882, 27882 (1973).
81Protection of Human Subjects, 38 FED. REG. 31738, 31738 (1973).
82See id.
83See Protection of Human Subjects, 39 FED. REG. 18914, 18914 (1974) (to be codied
at 45 C.F.R. x 46); See also Lederer & Grodin, supra note 44, at 19.
15the subjects would be protected, and whether there would be legally eective
informed consent.84
On July 12, 1974, Congress passed the National Research Act.85 Ti-
tle two of the Act established the National Commission for the Protection of
Human Subjects of Biomedical and Behavioral Research (the Commission) to
study and identify ethical principles for research on human subjects and then
make recommendations for appropriate guidelines.86 The Commission was also
supposed to propose requirements regarding informed consent of children, pris-
oners, and the mentally inrm.87
In 1976, the FDA promulgated regulations requiring Institutional Re-
view Boards (IRBs) to examine all studies using institutionalized subjects.88
After being advised by the Commission, in 1981 this regulation was amended to
require IRB review for all studies of FDA-regulated products before they could
be tested on humans.89
The Commission also developed a Report and Recommendations re-
garding research involving children, which was published in the Federal Register
on January 13, 1978.90 The report stated that
research involving children is important for the health and
well being of
children but... such research [should] be conducted only if it
is scientically sound, will contribute signicantly to generalizeable
84See Protection of Human Subjects, 45 C.F.R. x 46.2 (1974).
85Pub. L. No. 93-348, 88 Stat. 342 (1974).
86See id. See also Lederer & Grodin, supra note 44, at 19.
87See Pub. L. No. 93-348, 88 Stat. 342 (1974).
88See Thompson, supra note 71.
89See id. at 2.
90See Protection of Human Subjects: Research Involving Children; Report and Recommen-
dations of the National Commission for the Protection of Human Subjects of Biomedical and
Behavioral Research, 43 FED. REG. 2084 (1978).
16knowledge, risks are minimized, and the research performed in connec-
tion
with necessary treatment wherever possible. Adequate provisions must
be made to obtain the assent of the child and the consent of the par-
ents or
guardians.91
The Commission recognized the tension between the need for research on
children and the vulnerability of children.92 The Commission felt that children
should be involved in research because adult and animal models would not be
sucient for conducting research since some diseases are limited to children and
since children are not merely small adults.93 The Commission, however, rec-
ognized the need for Review Board safeguards.94 A rule with these safeguards
was proposed on July 21, 1978.95 The nal rule was promulgated on March
8, 1983.96 It implemented additional responsibilities for Institutional Review
Boards when children were subjects in the research.97 This rule essentially re-
mains in eect today.98
The early eighties was a time when Congress enacted statutes attempt-
ing to help children. In response to the large increase in the number of children
in foster care, the Adoption Assistance and Child Welfare Act of 198099 was
enacted to provide government funds for preventive services so that families
could remain intact. The Act required states to make reasonable eorts to keep
91Id.
92See id. at 2085.
93See id. at 2088.
94See id. at 2085.
95See Protection of Human Subjects; Proposed Regulations on Research Involving Children,
43 FED. REG. 31786 (1978).
96See Additional Protection for Children Involved as Subjects in Research, 48 FED. REG.
9814 (1983) (codied at 45 C.F.R. x 46.401{409).
97See id.
98See 45 C.F.R. 46.401{409 (1996). See discussion infra Part IV(A)(2).
99Pub. L. No. 96-272, 94 Stat 501 (1980).
17children with their families by saying that children could only be removed after
reasonable eorts to reunify and by saying that for states to be eligible for federal
reimbursement, they had to provide preventive and reunication services.100 By
the late 1980s, the federal government saw that this system failed to live up to
its expectations because the Act attempting to encourage permanency planning
led to an eagerness to place children in foster care instead of providing them
with the \prevention of placement services" they needed.101 Thus, with more
money available for foster care, many more children had been placed outside of
their homes and did not have permanent families. The 1983 Regulation, Addi-
tional Protections for Children Involved as Subjects in Research, may have also
had unintended consequences for children; now children are not used enough as
subjects in research, leaving holes in the scientic data regarding the safety and
eectiveness of drugs for children.
B. The History of Labeling Drugs for Pediatric Use
The history of labeling drugs parallels the history of the Food and
Drug Administration. As the FDA gained authority and discretion to regulate
food, drugs, devices, and cosmetics, it increased its regulatory hold over drug
labeling. Finally, in 1994 the FDA had expanded this scope to include labeling
of pediatric use.
It was not until the late nineteenth century that federal jurisdiction
was seen as encompassing regulation of the safety and eectiveness of food and
drugs.102 Concerns about safety after the tetanus-infected diphtheria antitoxin
100See id.
101Levesque, supra note 66, at 19.
102See Mr. Peter Hutt, Lecture in \Food and Drug Law" at Harvard Law School Winter
18killed children103 led to The Biologics Act of 1902,104 which required licensing
for biological products sold in interstate commerce. It was not until industry
concern over the prevention of adulteration so that competitors could have fair
playing elds that Congress enacted the 1906 Federal Food and Drugs Act.105
This statute, however, gave the FDA very limited power; essentially the FDA
was given enforcement power to police adulterated and misbranded products.
106 As far as drug labels, the Act said that a drug was misbranded if its label
contained false statements about its ingredients.107
Soon after the New Deal and the deaths of almost one hundred people
taking the untested sulfanilamide elixir, came the passage of the 1938 Federal
Food, Drug, and Cosmetics Act (FDCA).108 Now the FDA had the authority to
regulate the safety and eectiveness of drugs manufacturers considered newly
developed.109
The FDA soon created the distinction between prescription and over
the counter drugs.110 The FDCA required labeling to include both directions for
use and warnings of possible harms from using the drug.111 Exempt from this
provision were the prescription drugs, those that the FDA believed could not
Session (Jan. 6, 1997).
103See Hayes, supra note 61, at 60.
104Pub. L. No. 57-244, 32 Stat. 728 (1902).
105Pub. L. No. 59-384, 34 Stat. 768 (1906).
106See Annette, L. Marthaler, The FDA Defense: A Prescription for Easing the Pain of
Punitive Awards in Medical Products Liability Cases, 19 Hamline L. Rev. 451, 462 (1996).
107See Hayes, supra note 61, at 60.
108See id.; Pub. L. No. 75-717, 52 Stat. 1040 (1938) (currently codied at 21 U.S.C. xx 301
to 392).
109See Marthaler, supra note 105, at 463.
110See Charles J. Walsh, Steven R. Rowland, & Howard L. Dorfman, The Learned Interme-
diary Doctrine: The Correct Prescription for Drug Labeling, 48 Rutgers L. Rev. 821, 825
(1996).
111See id..; Pub. L. No. 75-717, 52 Stat. 1040, 1050-51 (1938) (currently codied at 21
U.S.C. x 352(f)).
19feasibly be labeled for patients to choose to use safely.112 In addition, the FDA's
enforcement powers grew as it developed administrative procedures to achieve
compliance.113 In time, the concept of misbranding expanded to include failure
to reveal \material facts." 114 The 1951 Durham-Humphrey Amendments to
the FDCA mandated that certain drugs needed to be prescribed by medical
professionals. Prescription drug labels were required to contain \adequate in-
formation concerning [the drug's] safety and eectiveness for its intended use
by the practitioner who dispenses."115 In addition, the label needed to provide
directions for use and to fully disclose any warnings.116
The 1962, Kefauver-Harris amendments to the FDCA, signicantly
changed the way that the FDA regulated the labeling of drugs.117 The FDA
began to base the approval of New Drug Applications (NDAs) on the labels
submitted. Thus, all drugs had to be approved or generally recognized as safe
based on substantial evidence that the drugs were both safe and eective.118
This gave the FDA a uniform requirement for labeling claims.119
On April 7, 1975, the FDA proposed a rule regarding the labeling for
prescription drugs used in people.120 The proposal was to improve prescription
drug labels by requiring a specic format.121 The label would have sections, such
112See Walsh et al., supra note 109, at 825.






119See id. at 62; David G. Adams, FDA Regulation of Communications on Pharmaceutical
Products, 24 Seton Hall L. Rev. 1399, 1404 (1994).
120See Labeling for Prescription Drugs Used in Man; Proposed Format for Prescription-Drug
Advertisements, 67 FED. REG. 15392 (1975).
121See id.
20as \Clinical Pharmacology," \Indications and Usage," \Adverse Reactions," and
\Precautions."122 When the nal rule was promulgated on June 26, 1979 the
regulations required categories of information on the label and specied that
labeling claims needed to come from testing on humans when feasible. 123
This 1979 regulation did address the issue of pediatric use in section
201.57(f)(9).124 This regulation said that if there was a specic pediatric indi-
cation it should be described in the \Indications and Usage" section and then
the appropriate pediatric dosage should be listed in the \Dosage and Admin-
istration" section of the labeling.125 But, for pediatric use to appear on the
label there needed to be \substantial evidence derived from adequate and well-
controlled studies."126 Thus, most prescription drugs did not contain pediatric
doses on the labels because the required clinical trials of children were not avail-
able.127
The 1990 study by the American Academy of Pediatrics, which found
that 80% of the drugs approved between 1984 and 1989 had no information on
pediatric use, was the impetus for the October 16, 1992 FDA proposal to amend
the \Pediatric Use" subsection of the Labeling regulations.128 The FDA's con-
cerns were similar to the concerns about the lack of drug testing on children;
[w]ithout adequate information, physicians may be reluctant to pre-
122See id. at 15393.
123See Labeling and Prescription Drug Advertising; Content and Format for Labeling for
Human Prescription Drugs, 44 FED. REG. 37434, 37434 (1979) (to be codied at 21 C.F.R.
xx 201-202); Hayes, supra note 61, at 62.
12421 C.F.R. 201.57(f)(9) (1979).
125Id.
126Id.
127See Williams, supra note 18.
128See Specic Requirements on Content and Format of Labeling for \Pediatric Use" Sub-
section in the Labeling, 57 FED. REG. 47423, 47423 (1992).
21scribe
certain drugs at all for their pediatric patients, or may prescribe them
inappropriately, choosing dosages, for instance that are arbitrarily
based
on the child's age, body weight, or body surface area without regard
for the interaction of those factors or age-related physiological and
biochemical factors. As a result, children may be exposed to an in-
creased
risk of adverse reactions, or decreased eectiveness of prescription
drugs,
or may be denied access to valuable therapeutic agents.129
The FDA had nally recognized that due to the problems related to testing
drugs on children,130 studies meeting the stringent standards in the 1979 reg-
ulation on pediatric use were dicult to obtain.131 Thus, the goal of the 1992
proposed regulation was to encourage pharmaceutical companies to increase the
labeling of drugs for pediatric use.132
On December 13, 1994, a nal regulation was promulgated revising the
\Pediatric Use" subsection of the prescription drug labeling requirements.133 By
December 13, 1996, manufacturers were to submit supplemental labeling appli-
cations if substantial evidence of safety and eectiveness could be extrapolated
to children from adults.134 In addition, if there was no substantial evidence of
pediatric use, the label was to indicate this fact.135
Over time, the FDA has been able to increase its authority to regulate
129Id.
130See discussion supra , Part II(A).
131See Specic Requirements on Content and Format of Labeling for \Pediatric Use" Sub-
section in the Labeling, 57 FED. REG. at 47423.
132See id.
133See Specic Requirements on Content and Format of Labeling for Human Prescription
Drugs; Revision of Pediatric Use Subsection in the Labeling, 59 FED. REG. 64240 (1994)
(codied at 21 C.F.R. 201.57(f)(9).
134See id.
135See id. See discussion infra Part IV(B).
22the food and drug supply. This has nally enabled the FDA to promulgate a
regulation that attempts to make drugs safer and more eective for children.
Due to the limited amount of testing on children to determine appropriate pe-
diatric dosages and the fact that pharmaceutical companies have extended the
compliance date of this regulation,136 it is clear that more needs to be done in
this area.
IV. THE CURRENT STATUS REGARDING DRUG TESTING ON
CHILDREN AND LABELING DRUGS FOR PEDIATRIC USE
\
Without pediatric studies or other sources of scientic information, labeling
cannot include guidance about dosage, side eects, and when a drug should or
should not be used in children."137 The most recent regulations are an attempt
to encourage pharmaceutical companies to develop the pediatric information
from clinical trials on children or extrapolation from adults so that this criti-
cal information can be included on the labels of medications.138 As of today,
these regulations have not succeeded in alleviating the need for data regarding
pediatric use. This section will examine both the current regulations and the
current conditions regarding both drug testing on children and labeling drugs
for pediatric use.
136See FDA Pediatric Use Supplement Submission Deadline Extended, 59 F-D-C Rep.,
(\The Pink Sheet"), Jan. 6, 1997, at T&G 6.
137Flieger, supra note 22.
138See id.
23A. An Analysis of the Current Regulations for Protecting Children Involved
as Subjects in Research
The nal rule approved in 1983 essentially remains the same today.139
Subpart D of the Protection of Human Subject Guidelines, entitled Additional
Protections for Children Involved as Subjects in Research, enumerates impor-
tant guidelines to protect the welfare of children.140
1. Background Information: Sections 46.401 through 46.403
Section 46.401 establishes that Subpart D applies to all research con-
ducted or supported by the Department of Health and Human Services that
involves children as subjects.141 Section 46.402 denes important terms.142
Children are those who have not reached the legal age for consent to the re-
search as per the laws of the applicable jurisdiction.143 Assent is dened as a
\child's armative agreement to participate in research. Mere failure to object
should not, absent armative agreement, be construed as assent."144 Permis-
sion is then the agreement by the child's biological or adoptive parent(s) or
guardian.145 Section 46.403 expands the responsibilities of the Institutional
Review Boards (IRBs) to include research involving children as subjects.146
2. Determining Whether the Research Can and Should Be Done on Chil-
dren; A Look at the Guidelines, IRBs, and the Requirements: Sections 46.404
139See Additional Protection for Children Involved as Subjects in Research, 48 FED. REG.
9814 (1983) (codied at 45 C.F.R. xx 46.401{46.409).
140See id.
141See id. x 46.401.
142See id. x 46.402.
143See id. x 46.402(a).
144Id. x 46.402(b).
145See id. x 46.402(c)-(e).
146See id.x 46.403.
24through 46.407.
The next four sections address the level of risk to the child involved
in research that the Department of Health and Human Services will conduct or
fund.147 Section 46.404 says that the Department of Health and Human Services
will only conduct or fund research that the IRB nds has no greater than a min-
imal risk to children if there have been proper attempts to solicit assent from the
children and permission from the parents.148 Section 46.405 allows for research
on children when there is a greater than minimal risk but the potential for direct
benet to the subjects149 provided that the IRB nds \[t]he risk is justied by
the anticipated benets,"150 \[t]he relation of the anticipated benet to the risk
is as least as favorable to the subjects as that presented by available alternative
approaches,"151 and there have been the appropriate attempts to solicit both
the assent of the child and the permission of the parent(s) or guardian(s).152
Section 45.406 is relevant to research that involves a greater than minimal risk
and has no anticipated benet to the individual child subjects, but is likely to
\yield generalizeable knowledge about the subject's disorder or condition."153
In this case, the Department of Health and Human Services will acquiesce with
the project only if the IRB has found that
(a) The risk represents a minor increase over minimal risk;
(b) The intervention or procedure presents experiences to subjects that
are reasonably commensurate with those inherent in their actual or ex-
147See id. x 46.404-407
148See id. x 46.404.






medical, dental, psychological, social or educational situations;
(c) The intervention or procedure is likely to yield generalizeable knowl-
edge
about the subjects' disorder or condition which is of vital importance
for the understanding or amelioration of the subjects' disorder or con-
dition; and
(d) Adequate provisions are made for soliciting assent of the children
and
permission of their parents or guardians...154
Lastly, Section 46.407 provides a catch-all for the Department of Health and
Human Services to conduct or fund research not covered by the three sections
outlined above.155 As per this section, research is permissible if the Secretary
(after consulting with a panel of experts from a variety of disciplines such as law,
medicine and ethics) and the IRB nd that \[t]he research presents a reasonable
opportunity to further the understanding, prevention, or alleviation of a serious
problem aecting the health or welfare of children"156 and that the Secretary
(after consolation) nds that the research \will be conducted in accordance with
sound ethical principles,"157 and that proper steps will be taken to get assent
from the children and permission from the parent(s) or guardian(s).158
These four sections, Sections 46.404 through 46.407, set guidelines for
determining whether proposed research may be done on children.159 Essen-
tially then, Institutional Review Boards (IRBs) control the access children have
to being part of clinical drug trials.160 This is especially true because even
154Id.
155Id. x 46.407.
156Id. x 46.407(a); x46.407(b)(i).
157Id. x 46.407(b)(ii).
158Id. x 46.407(b)(iii).
159See id. x 46.404-407.
160See Dale L. Moore, An IRB Member's Perspective on Access to Innovative Therapy, 57
Alb. L. Rev. 559, 559 (1994).
26though the aforementioned federal guidelines for IRBs only refer to research
funded or conducted by the Department of Health and Human Services, many
IRBs do not evaluate federally-sponsored and privately-sponsored research pro-
posals dierently.161 One IRB member, Dale Moore, who has written on this
issue said, \[w]e must be particularly vigilant about protecting vulnerable pop-
ulations, including children, prisoners, pregnant women, the mentally disabled,
and those who are economically or educationally disadvantaged. The vulnera-
bility of people in these groups stems from their susceptibility to exploitation or
coercion."162 While there are concerns about protecting \vulnerable" people,
Moore acknowledged that child welfare mandates the use of children in drug
testing.163 Thus, in his opinion, the key is to make sure that IRBs act as \ad-
vocates for the research subjects."164
The regulations and the IRBs are not the major problem when it comes
to ensuring research involving children is not disadvantageous. The FDA has
come to see the importance of testing drugs on children. For example, the FDA
has recently added a \pediatric page" to its review of NDAs so that there is
a summary of what is known about the drug with respect to children.165 The
greater diculty is getting institutions to test the drugs in the rst place, leav-
ing most drugs with disclaimers saying that safety and eectiveness have not
been established for use in children.166 For economic reasons, institutions tend
161See id. at 564.
162Id. at 565.
163See id at 570.
164Id. at 572.
165See Drug Testing in Children, supra note 5.
166See id.
27not to perform clinical trials on children.167 Thus, for children to have access
to the drugs they need in appropriate dosages, more clinical testing is needed.
The National Institute of Child Health and Human Development (NICHD)
has now established a network of six research sites that are providing clinical
data on drug use in children.168 Dr. Duane Alexander, director of NICHD
says that the goal of this program is to increase the number of drugs tested on
children and then ultimately approved by the FDA for use in children so that
eventually, \all drugs prescribed for children [will] have been evaluated and ap-
proved specically for such usage."169
In 1994, the American Academy of Pediatrics' Committee on Drugs
gave the FDA a list of six drugs that most crucially needed to be approved
for children. These drugs include three anesthetics: midazolam (Versed), bupi-
vacaine (Sensorcaine), and fantanyl which are all used in emergency settings
for surgery, bone-setting, or diagnostic procedures such as CAT-scans.170 The
other three drugs were Flagyl (an antibiotic), Tagament (an ulcer medication)
and albuterol (an asthma medication).171
3. Child's Assent and Parent(s)' Permission: Section 46.408
The regulations for using children as research subjects also address the
issues of assent and permission for participation in Section 46.408.172 Here it
says that the IRB must determine whether a child is capable of assenting and if
167See id; Wielawski, supra note 13, at E1. See also Kessler, supra note 1 at 330.
168See Ostrowidski, supra note 2, at 1.
169Id.
170See Elizabeth Stone, Children's Labels Reconsidered, N.Y. Times, Jan. 25, 1995, at C11.
171See id.
17245 C.F.R. x 46.408 (1996).
28so, whether the assent has been adequately solicited.173 In making this decision
the IRB will take into account age, maturity, and psychological state for each
child individually or for all children to be involved in the study.174 If the IRB
nds that the child is not capable of assenting, the assent requirement can be
waived.175
The IRB must also determine whether parent(s)' permission was ad-
equately sought.176 If the research has no greater than a minimal risk to the
child (x46.404) or the research has a greater than minimal level of risk, but
would be of direct benet to the child participating (x46.405), the permission
of one parent is needed. If, however, the research is not meant to directly ben-
et the child (xx 46.406 and 46.407), the permission of both parents is required
unless one is deceased, unknown, incompetent, not reasonably available, or if
only one parent has legal responsibility for the child.177 The IRB can determine
that the research does not need parental permission so long as there is another
mechanism to protect the child participants and this is consonant with state
and federal law.178
A child's assent (or lack thereof) is of great value in determining
whether the research should be done. Some children, however, are powerless
when it comes to these choices, especially younger children.179 In general, chil-
dren are opposed to medical care. Crying, screaming, and tantrums are common
173See id x 46.408(a).
174See id.
175See id.
176See id. x 46.408(b).
177See id.
178See id. x 46.408(c).
179See Moore, supra note 160, at 569.
29occurrences for children at the doctor's oce. A child's resistance to medical
treatment may sometimes be ignored, which could be in the child's best inter-
est.180
There are instances where a parent's lack of permission can be over-
ridden by a child's assent. Some states have lowered the age at which minors
can consent to medical treatment.181 The law has been increasingly recogniz-
ing that age is arbitrary and that therefore, some decisions should be based
on maturity.182 The federal regulations recognize that there are some children
that should make their own choices regarding their participation in research
studies.183
4. Children Who are Wards of the State: Section 46.409
Section 46.409 allows children who are wards of the state to be included
in research if the research is related to their status as wards, or if the research
is conducted in settings such as schools, camps, and, hospitals, or institutions
where most children are not wards of the state.184 If the ward of the state is
involved as a subject in research as described above, the IRB will appoint an
advocate for each ward, who will act in the child's best interest.185 Thus, for
a child in foster care to be involved in a clinical trial, the research must either
pertain to the child's status as a ward of the state or the research must involve
180See id. at 574.
181See Glantz, supra note 21, at 112. See, e.g., Younts v. St. Francis Hospital, 469 P.2d
330 (Kan. 1970) (holding that a seventeen year old minor was mature enough to consent to a
benecial skin graft treatment); In re E.G., a minor, 549 N.E.2d 322 (Ill. 1989) (holding that
a seventeen year old Jehovah's Witness with leukemia could refuse blood transfusions).
182See id. at 113.
183See id.; 45 C.F.R. x 46.408.
184See 45 C.F.R. x 46.409(a).
185See id. at 46.409(b).
30both children who are wards and children who are not as well as take place in
a school, camp or hospital.186 Most likely, these regulations are an attempt to
protect foster children from the exploitation wards had experienced in earlier
times, by prohibiting the exclusive use of wards of the state in pediatric research,
while recognizing the need for these children to participate as subjects.187
AIDS drug testing is an example showing that the reality of the situa-
tion is a bit more bleak. While wards of the state were clearly taken advantage
of in earlier times,188 these children now do not have enough access to partici-
pation in clinical trials.189
In 1994 there were approximately one million children worldwide in-
fected with the HIV virus and by the year 2000 there will be about ten million
children suering.190 In the United States there are currently about 10-20,000
children with HIV.191 HIV infected foster children make up almost half of these
children,192 yet a 1989 nationwide study found that only two percent of the
children participating in AIDS related clinical trials were in foster care.193
When foster children enter the system, they often lose contact with
their biological parents, yet remain in \foster care drift" for an average of 5.7
years.194 The result is that the children are unable to obtain parental consent to
186See id. at 46.409(a).
187See Briar McNutt, The Under-Enrollment of HIV-Infected Foster Children in Clinical
Trials and Protocols and the Need for Corrective State Action, 20 Am. J. L. and Med. 231,
241 (1994).
188See discussion infra Part III(A).
189See McNutt, supra note 187, at 231.
190See id.
191See id.
192See id. at 237.
193See id. at 231.
194The average length of time from when a child rst enters foster care in Massachusetts
until the child's adoption is legalized is 5.7 years. Report by the Probate and Family Court,
Honorable Mary C. Fitzpatrick, Chief Justice, Termination of Parental Rights Cases in the
31participate in the drug testing.195 While the federal regulations on children as
research subjects would not prohibit participation, most child protection agen-
cies do not have the authority to consent to treatment with investigational or
experimental drugs.196 Therefore, at this time there is a large segment of the
HIV population unable to obtain access to new drug therapies.
B. An Analysis of the Current Regulation of Labeling Drugs for Pediatric
Use
The FDA is in the midst of revolutionizing drug labeling so that
medical professionals will be cognizant of appropriate pediatric doses and safety
hazards. On December 13, 1994, the FDA promulgated a nal rule revising the
\Pediatric Use" subsection of labeling drugs.197 The purpose of this new regula-
tion was to change the 1979 regulation which only permitted pediatric claims if
there had been adequate and well-controlled studies of the drug on children.198
This old regulation had, contrary to its purpose, stymied the hope that drug
labels would provide adequate information for using drugs in children.199 The
new regulation oers much more promise that drugs will be labeled with more
pediatric information, information that is critical to the well-being of so many
of our nation's youngest.
The new regulation, eective January 12, 1995, revamped drug la-
Probate and Family Court: Recommendations for Improvements to the System (March 1,
1995).
195See McNutt, supra note 187, at 242.
196See id.
197See Specic Requirements on Content and Format of Labeling for Human Drugs; Revision




32beling for pediatric use.200 The regulation upheld the earlier requirement so
that if there was a specic pediatric indication supported by adequate and
well-controlled studies in the pediatric population, this would appear on the la-
bel.201 In addition, the FDA could now approve a drug for pediatric use based
on adequate and well-controlled studies in adults if other information support-
ing pediatric use was provided and the FDA determined that the course of the
disease and the eects of the drug were similar in adults and children.202 Also,
if there was not substantial evidence to support a pediatric indication or a pedi-
atric use statement for any children, (or for a specic age group), the \Pediatric
Use" subsection of the label will need to say that \safety and eectiveness in
pediatric patients [or the age group] have not been established."203
Sponsors of drugs were given until December 13, 1996, two years af-
ter the nal regulation was promulgated, to look at their data and determine
whether the \Pediatric Use" subsection should be updated to include infor-
mation supporting pediatric use based on studies in adults, and then submit
a supplemental application to the FDA.204 Thus, if there is adequate data to
support pediatric use, sponsors should seek supplemental claims; if there is not
substantial evidence to support pediatric use then the label should state this;
and if there is no reason for a \Pediatric Use" subsection on the label, the spon-
sor should justify its omission to the FDA.205 In essence, as FDA Commissioner,
200See id.
201See 21 C.F.R. 201.57(f)(9)(ii)-(iii) (1996).
202See id. at 201.57(f)(9)(iv).
203Id. at 201.57(f)(9)(v)-(vi).
204See Pediatric Use Drug Labeling NDA Supplements Due By December 1996{ FDA Final
Rule, 56 F-D-C Rep. (\The Pink Sheet"), Dec. 19, 1994, at 3.
205See id. at 4.
33David Kessler, said when the nal rule was announced at the Food and Drug
Law Institute annual meeting,
\[t]he new rule also allows the FDA to approve a drug for pediatric
use
when the course of a disease is similar in adults and children, and the
sponsor provides supporting pediatric information.... So, if the
disease behaves the same in adults and children, adequate and well-
controlled
trials to show ecacy may not need to be repeated in children. All
that may
be necessary under the new rule is information on the appropriate dose
for
children and perhaps some additional safety information.206
On November 6, 1996, after very little response to the nal rule, the FDA
sent letters to 250 drug manufacturers asking them to tell the agency if they
planned to le supplements, and if so when.207 As of December 30, 1996, only
40 of the pharmaceutical companies had responded to the FDA's letter.208 On
November 20, 1996, the Pharmaceutical Research and Manufacturers of Amer-
ica (PhRMA) asked the FDA to extend the compliance date because some of
its members with a lot of dierent products, were having trouble gathering the
necessary information.209
The FDA, knowing compliance is essential to the success of their new
pediatric use labeling requirement, decided to extend the compliance date of
the nal rule to April 7, 1997.210 Those manufacturers who let the FDA know
206See Kessler, supra note 1, at 330.
207See FDA Pediatric Use Supplement Submission Deadline Extended, 59 F-D-C Rep.
(\The Pink Sheet"), Jan. 7, 1997, at T&G-6; Specic Requirements on Content and For-
mat of Labeling for Human Prescription Drugs; Revision of \Pediatric Use" Subsection in the




34in writing by January 29, 1997 that they intend to submit supplemental appli-
cations for their products, will have until April 7, 1997 to gather the required
data.211 As of this date, it remains to be seen just how much compliance there
will be; therefore, it is not clear how successful this new regulation will be.
\The absence of adequate pediatric labeling continues to present a sig-
nicant public health issue and the level of response to the December 13, 1994,
nal rules is cause for concern," read the Federal Register when the FDA de-
cided to extend the compliance date.212 The nature of the problem is that the
information regarding pediatric use is just not available with regard to many,
many drugs commonly used in children. Doctors had been \guesstimating"
doses. Now manufacturers asked for information regarding the pediatric use of
drugs cannot nd the adequate data. Why? Because the data does not exist.
And the reason for this is that the pharmaceutical companies do not want to
pay for the research because the market for children's drugs is not sucient to
compensate for the costs of the studies. Thus, it is quite possible that even with
this new regulation, making it substantially easier to label drugs for pediatric
use, the crucial information will still not be available to medical professionals.
V. MAKING DRUGS MORE SAFE AND EFFECTIVE FOR USE IN
CHILDREN: SOME RECOMMENDATIONS FOR INCREASING DRUG
TESTING ON CHILDREN AND LABELING DRUGS FOR PEDIATRIC
211See id.
212Specic Requirements on Content and Format of Labeling for Human Prescription Drugs;
Revision of \Pediatric Use" Subsection in the Labeling; Extension of Compliance Date, 61
Fed. Reg. 68623, 68623 (1996).
35USE
FDA Commissioner, David Kessler, referred to the new pediatric labeling
regulation as \only a rst step."213 Hopefully the new FDA Commissioner will
agree with that statement because there is a lot more that needs to be done
to ensure that our children can use safe and eective drugs in the appropriate
doses. An analysis of this issue reveals several recommendations for combating
the lack of information available regarding the pediatric use of drugs.
A. Increase the Length of Exclusivity for Manufacturers Who Have Their Drugs
Approved for Pediatric Use
If a major obstacle to testing drugs on children is that it is not econom-
ically feasible for drug manufacturers to do the studies, then providing nancial
incentives for drug testing on children could eventually lead to enough data for
most drugs to be labeled for pediatric use. One way to provide nancial
incentives for manufacturers to test their drugs on children is to treat this prob-
lem similarly to the testing of \orphan drugs" by providing increased market
exclusivity.
Orphan drugs are those that are necessary to treat \rare disease[s] or
condition[s]," meaning diseases or conditions aicting less than 200,000 people
in the United States or aicting more than 200,000 people but with no rea-
sonable expectation that the cost of developing and making the drug can be
213Kessler, supra note 1, at 330.
36recovered through sales.214 These drugs are given market exclusivity for seven
years215 which prevents other companies from piggybacking on their expensive
research for a longer period of time than just when the patent would dictate.
In addition, sponsors of such drugs can obtain open protocols for investigations
on those with the disease or the condition.216 Lastly, the Secretary of the De-
partment of Health and Human Services can contract with or give grants to the
drug sponsor in an eort to defray the costs of testing orphan drugs.217
In 1992, as the FDA was proposing the regulation to change pediatric
use labeling, Senator Nancy Kassebaum sponsored the \Better Pharmaceuticals
for Children Act," as an attempt to expand the orphan drug concept to testing
drugs on children.218 On October 5, 1992, Senator Kassebaum's statements
were read to Congress. She explained that, [w]ith the exception of certain drugs
with known and signicant pediatric uses, pharmaceutical product are seldom
studied in younger populations,"219 leaving the physicians to estimate safe and
eective dosages for children even though children metabolize drugs dierently
from adults.220 The Senator claimed that the reason for this lack of information
was that manufacturers had little incentive to do studies on drugs which they
were not intending to market for children; those that they expected little addi-
214Federal Food, Drugs, and Cosmetics Act, 21 U.S.C. x 360bb (1996).
215See id. x 360cc.
216See id. x 360dd.
217See id. x 360ee.
218See S. 3337, 102nd Cong. (1992); 54 F-D-C- Rep. (\The Pink Sheet"), October 19, 1992,
at 5.
219Statements on Introduced Bills and Joint Resolutions, Better Pharmaceuticals for Chil-
dren Act, S. 3337, 102nd Cong., 138 Cong. Rec. S16998, S16998 (1992) [hereinafter State-
ments] (statements of Senator Nancy Kassebaum).
220See id.
37tional revenue to come from the pediatric population.221 This, she said, leaves
children as \therapeutic orphans."222
The Kassebaum bill would have provided incentives for manufacturers
to test drugs on children. Essentially, any drug not ordinarily studied in chil-
dren (so, not antibiotics, anti-asthamic medications, anti-allergy medications,
or drugs developed for diseases or conditions only occurring in children), would
qualify for an additional six months of exclusivity provided that the FDA had
approved the pediatric studies.223
Incentives are clearly needed for manufacturers to test their drugs on
children. Eighty percent of the more than 2000 prescription drugs approved by
the FDA have not been tested for safety or eectiveness in children.224 Only
three of the nine AIDS drugs being sold have been approved for children.225
The major reason for this travesty seems to be a lack of economic incentives for
drug manufacturers to invest in such research. Thus, if conducting these trials
could be made protable for manufacturers, the benets to children could be
enormous. The concept of extending exclusivity is not a new one; it has been
successful in the realm of orphan drugs226 and could probably be as successful
for pediatric use of drugs. Unfortunately, the Better Pharmaceuticals for Chil-
dren Act did not get much past the Senate Floor of the 102nd Congress. Similar
legislation needs to be introduced again, with a sponsor who will push the issue
221See id at S16999; 54 F-D-C Rep. (\The Pink Sheet"), October 19, 1992, at 5.
222Statements, supra note 217, at S16999.
223See id.; S. 3337; 54 F-D-C Rep. (\The Pink Sheet"), October 19, 1992, at 5.
224See Stone, supra note 31, at A1.
225See Gordon, supra note 27, at A1.
226See Hearings, supra note 217, at S16998.
38so that drug testing on children will be a reality that will ultimately end with
pediatric use on drug labels. As Senator Kassebaum stated, \I know each of us
would do anything to help a sick child, and an incentive for drug sponsors to
perform pediatric studies takes a step in that direction."227
B. Mandate Testing of Some Drugs and/or Mandate Label Supplements Indi-
cating Pediatric Use
The fact that eighty percent of the approved drugs have not been tested
for safety or eectiveness in children228 obviously cannot be remedied over night.
We are quite far from the FDA goal that \whenever a child receives medication,
it is as safe and eective as possible."229 One way to manageably resolve this
problem, would be for the FDA (or a child-oriented, health organization) to pri-
oritize which drugs should be dealt with immediately and then work from there
to eventually have them all approved for pediatric use either through testing on
children or when feasible, extrapolating from adults. Perhaps Congress could
provide some of the funds for the testing.
Some steps have been taken in this direction. In 1994, in response to
an FDA request, the American Academy of Pediatrics submitted a list of the
six drugs believed to most desperately need testing in children.230 These identi-
ed drugs were targeted because of their frequent use, potential safety hazards,
and their therapeutic importance to children.231 An IND for an oral syrup ver-
227See id. at S16999.
228See Rule Would Help Doctors, supra note 10, at 6.
229Williams, supra note 18.
230See Stone, supra note 31, at A1.
231See FDA Seeking Advisory Committee Input to Identify Drugs for Pediatric Indications,
58 F-D-C Rep. (\The Pink Sheet"), Dec. 23, 1996, at 18.
39sion of the anesthesia, Versed, one of the six drugs identied by the American
Academy of Pediatrics, was led in December of 1996.232 The FDA hopes to
approve this application in 1998.233 In January of 1997, Paula Botstein, now the
Acting Director of the FDA's Oce of Drug Evaluation III, explained that one
of the \next steps" in updating pediatric labeling is that the FDA is considering
advisory committees which would identify the drugs that need pediatric indica-
tions.234 Botstein then explained the agency's eorts in this area by discussing
the FDA's success in obtaining a pediatric use supplement for Versed.235
This eort does not seem sucient. Of the almost 1600 drugs not yet
approved for children,236 the American Academy of Pediatrics selected six crit-
ical drugs to be tested for pediatric use. Two years after the improved labeling
regulation, only one of these six drugs has a pediatric supplement and the IND
will not be approved until 1998.
A very strong eort to encourage manufacturers to submit supplemen-
tal applications for pediatric labeling, by the April 7, 1997 compliance date could
reduce the number of drugs still lacking pediatric use information. From there,
the FDA will need to intensively pursue the task of collecting data for those
drugs that are used most frequently by children, possess the greatest potential
of safety hazards, and have the greatest therapeutic importance for children.
Grant money from Congress could help this process move more swiftly.
232See Roche Versed Pediatric Labeling Should Require \Dedicated Monitor" in Deep Se-
dation Cases, FDA Committee Says; Firm Submits IND for Oral Syrup Version, 58 F-D-C
Rep. (\The Pink Sheet"), Dec. 23, 1996, at 17.
233See id.
234See FDA Pediatric Use Supplement Submission Deadline Extended, 59 F-D-C Rep.
(\The Pink Sheet"), Jan. 6, 1997, at T&G-6.
235See id.
236See Rule Would Help Doctors, supra note 10, at 6.
40C. Create a Database of Information Relevant to Pediatric Use of Drugs
One major impediment for pharmaceutical companies attempting to
comply with the new pediatric use labeling regulation is that often, they really
do not have the data relevant to pediatric use. Health professionals who work
with children can be a great source of information because many have already
been prescribing these drugs for their pediatric patients. If the FDA could cre-
ate a database, physicians from all over the country could share the experiences
they have had using the drugs lacking data from clinical trials. In essence, since
pediatricians are currently relying on trial and error to estimate doses, it is as if
there are clinical trials being run throughout the country. If this was all entered
into one database, the FDA could come up with the proper dosages to make
drugs safe and eective for children.
Currently, there is a Pediatric Oncology Group which is a successful
data bank relevant to the use of cancer drugs in children.237 It would be ex-
tremely helpful for children if this concept could be expanded. Eventually, the
FDA could approve drugs for pediatric use and then label the drugs for pediatric
use, without requiring the manufacturers to sponsor expensive studies.
This system has some potential aws. First of all, it would take addi-
tional FDA resources to create a database. Secondly, compiling this information
could take a great deal of time. On the other hand, the current system is also go-
ing to take a tremendous amount of time, if it ever works. Physician compliance
is another potential problem, but it seems like it would be easier to enlist the
237See Wielawski, supra note 13, at E1.
41services of physicians than the pharmaceutical companies. Lastly, if the FDA
started to take responsibility for assessing pediatric use, manufacturers would
probably not test their new drugs on children. It would, therefore, be best if the
FDA database was only used to approve drugs that have already been on the
market and used on children and for experimental drugs. New drugs, however,
probably should not be included in the database. Instead, manufacturers should
be encouraged to test their drugs on children prior to having the drug approved
by the FDA.
D. Encourage Pediatric Testing During the Development of New Drugs
If more manufacturers had data regarding the pediatric use of drugs
during the development process, it would be much easier to label the drugs for
pediatric use once they were put on the market.
According to Paula Botstein, in 1995 the FDA was already routinely
asking FDA drug review divisions to nd the INDs with potential pediatric uses
and then encourage the drug companies to go through the process of having
these drugs approved for children.238 Ms. Botstein also said that the FDA
has created a \pediatric page," which is a summary of what is known about
a drug with respect to children used during NDA review.239 \It's basically a
management tool, so that FDA's own people will think more in terms of drugs
for children{ and to explore this potential with the drug sponsors."240
The problem here is that the FDA cannot do more than encourage




42pediatric use nor testing drugs in children are requirements for the approval of
NDAs. Amending the Federal Food, Drug, and Cosmetics Act to require drug
testing on children prior to drug approval, would probably slow down the ap-
proval process, keeping vital drugs o of the market.
Drug companies need to value children when they make their choices.
Perhaps if the FDA continues to encourage drug companies to investigate drug
eects on children, the mindset of manufacturers will shift. In addition, if the
FDA \encourages" drug companies through more expeditious and cooperative
review of NDAs containing information regarding pediatric use, manufacturers
might be urged to incorporate children's needs into their corporate decisions.
The key again is nancial incentives for drug manufacturers.
Perhaps, if there were these incentives for testing new drugs on children, Congress
could then provide some of the funds and create a data base for pediatric use
of drugs already on the market. In addition, the new labeling regulation makes
the approval process easier because drugs need not actually be tested in children
provided there is substantial evidence that the data can be extrapolated from
adults and that the course of the disease and the drug are similar in both chil-
dren and adults. Putting these concepts together, it is possible that eventually
there would be enough data on the safety and eectiveness of drugs in children
that most drugs could be labeled for pediatric use.
E. Strengthen the Institutional Review Boards (IRBs)
The thought of drug testing children still makes the public cringe. No
one thinks that children should be used as guinea pigs. Ethics is a real concern
43when it comes to drug testing and children. Public support of using children
in clinical trials is necessary if the proper resources are going to be available
for this mission. One way to increase public support would be to increase the
credibility of IRBs in the eyes of the public.
IRBs essentially determine whether research will be done using children
as subjects.241 Trust in this choice that could mean the dierence between the
life and the death of a child is imperative.
IRBs need to scrupulously analyze research applications when deciding
whether or not the research is permissible. This is especially true with vulnerable
populations, such as children. If IRBs are seen as adept, many of the ethical
concerns will be eliminated. More drug testing on children would be funded
both publicly and privately, if the public viewed this testing as both critical
and ethical. In addition, drug manufacturers would no longer be able to claim
that ethical concerns were the basis for their lack of testing; drug manufacturers
would have to face up to their choice not to do drug testing on children because
it is not cost-eective.242
CONCLUSION
Our society run by grown-ups has failed to protect the health and safety of
our children. Inevitably, children will need medications, but the chances are
241See Moore, supra note 160, at 559.
242See Wielawski, supra note 13, at E1.
44that the drugs prescribed will not have been approved for use in children. This
is unacceptable.
The problem is clear. Children metabolize and excrete drugs dierently
than adults. Therefore, determining dosages and safety hazards for children
typically requires testing in children. Since these tests are rarely done, most
drug labels tell pediatricians nothing about pediatric use.
We are at a critical time in history, a time when child welfare is on
political agendas. Thus, it is time to make some changes so that children will
have access to vital drugs in appropriate dosages.
The Food and Drug Administration nally sees the urgency for drug
testing on children and labeling drugs for pediatric use. Now political leaders
have the responsibility to make sure that the pharmaceutical companies respond.
We cannot leave the issue of drug testing on children to the market because it
is not protable for drug manufacturers to do the needed studies. A child's life,
however, is priceless. Steps need to be taken to make sure that when children
are given medication, the dosage is as accurate as possible. This is what adults
want and this is what adults generally get. Children deserve at least this much.
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